Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles
Is the Clinical Outcome Affected by the Incidence of Progesterone Elevation on the Day of hCG Triggering When Agonist Protocol is Compared to Antagonist Protocol for IVF
1 other identifier
interventional
200
1 country
1
Brief Summary
The aim is to explore whether the incidence of progesterone rise in the late follicular phase differs between GnRH-agonist and GnRH-antagonist protocols for IVF and whether this has an impact on the probability of pregnancy achievement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Jan 2007
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedFirst Submitted
Initial submission to the registry
August 27, 2010
CompletedFirst Posted
Study publicly available on registry
August 31, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2011
CompletedSeptember 15, 2010
January 1, 2009
4 years
August 27, 2010
September 14, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of late progesterone rise on the day of HCG triggering
Up to delivery (2010)
Secondary Outcomes (1)
Clinical pregnancy rate Delivery rate
Up to delivery (2010)
Study Arms (2)
Antagonist group
EXPERIMENTALAntagonist protocol for IVF
Agonist group
ACTIVE COMPARATORLong Agonist protocol for IVF
Interventions
In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
Eligibility Criteria
You may qualify if:
- age \< 39
- follicle-stimulating hormone (FSH) \< 12
- gonadotropin dose 100-300IU
You may not qualify if:
- endometriosis
- known endocrine disorder
- blood analyzed in another laboratory
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universitair Ziekenhuis Brussellead
- BioGenesiscollaborator
Study Sites (1)
Biogenesis
Thessaloniki, Pylaia, 55536, Greece
Related Publications (2)
Papanikolaou EG, Kolibianakis EM, Pozzobon C, Tank P, Tournaye H, Bourgain C, Van Steirteghem A, Devroey P. Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertil Steril. 2009 Mar;91(3):949-52. doi: 10.1016/j.fertnstert.2006.12.064. Epub 2007 Jun 6.
PMID: 17555751BACKGROUNDPapanikolaou EG, Pados G, Grimbizis G, Bili E, Kyriazi L, Polyzos NP, Humaidan P, Tournaye H, Tarlatzis B. GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Hum Reprod. 2012 Jun;27(6):1822-8. doi: 10.1093/humrep/des066. Epub 2012 Mar 14.
PMID: 22422777DERIVED
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Basil Tarlatzis, MD
BioGenesis
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 27, 2010
First Posted
August 31, 2010
Study Start
January 1, 2007
Primary Completion
January 1, 2011
Study Completion
January 1, 2011
Last Updated
September 15, 2010
Record last verified: 2009-01